PURPOSE: In the present study, we investigated the degree of protein expression and gene amplification of HER-2 in esophageal squamous cell carcinoma (SCC) cell lines and freshly isolated tumors, and trastuzumab-mediated biological activity, in particular antibody-dependent cellular cytotoxicity (ADCC) against HER-2-expressing esophageal SCC cell lines. EXPERIMENTAL DESIGN: Ten different SCC cell lines with various levels of HER-2 status evaluated by flow cytometry, immunocytochemistry (HercepTest), and fluorescence in situ hybridization were evaluated for ADCC, growth inhibitory, or apoptosis-inducing activities mediated by trastuzumab. RESULTS: Trastuzumab induced ADCC against HER-2-expressing esophageal SCC and the activities reflected the degree of HER-2 expression analyzed by flow cytometric analysis, but not by HercepTest nor fluorescence in situ hybridization analysis. Furthermore, trastuzumab-mediated ADCC against transforming growth factor-beta-producing SCC was enhanced by the treatment with SB-431542, which is a selective inhibitor of the phosphorylation induced by transforming growth factor-beta. There were very marginal effects of anti-proliferative or apoptosis-inducing activities mediated by trastuzumab for HER-2-expressing esophageal SCC. CONCLUSION: HER-2-expressing esophageal SCC cells could be killed by trastuzumab-mediated ADCC and the activity reflected the degree of HER-2 expression detected by flow cytometry.
PURPOSE: In the present study, we investigated the degree of protein expression and gene amplification of HER-2 in esophageal squamous cell carcinoma (SCC) cell lines and freshly isolated tumors, and trastuzumab-mediated biological activity, in particular antibody-dependent cellular cytotoxicity (ADCC) against HER-2-expressing esophageal SCC cell lines. EXPERIMENTAL DESIGN: Ten different SCC cell lines with various levels of HER-2 status evaluated by flow cytometry, immunocytochemistry (HercepTest), and fluorescence in situ hybridization were evaluated for ADCC, growth inhibitory, or apoptosis-inducing activities mediated by trastuzumab. RESULTS:Trastuzumab induced ADCC against HER-2-expressing esophageal SCC and the activities reflected the degree of HER-2 expression analyzed by flow cytometric analysis, but not by HercepTest nor fluorescence in situ hybridization analysis. Furthermore, trastuzumab-mediated ADCC against transforming growth factor-beta-producing SCC was enhanced by the treatment with SB-431542, which is a selective inhibitor of the phosphorylation induced by transforming growth factor-beta. There were very marginal effects of anti-proliferative or apoptosis-inducing activities mediated by trastuzumab for HER-2-expressing esophageal SCC. CONCLUSION:HER-2-expressing esophageal SCC cells could be killed by trastuzumab-mediated ADCC and the activity reflected the degree of HER-2 expression detected by flow cytometry.
Authors: C Larbouret; B Robert; C Bascoul-Mollevi; F Penault-Llorca; A Ho-Pun-Cheung; S Morisseau; I Navarro-Teulon; J-P Mach; A Pèlegrin; D Azria Journal: Ann Oncol Date: 2009-11-04 Impact factor: 32.976
Authors: David P Nusinow; John Szpyt; Mahmoud Ghandi; Christopher M Rose; E Robert McDonald; Marian Kalocsay; Judit Jané-Valbuena; Ellen Gelfand; Devin K Schweppe; Mark Jedrychowski; Javad Golji; Dale A Porter; Tomas Rejtar; Y Karen Wang; Gregory V Kryukov; Frank Stegmeier; Brian K Erickson; Levi A Garraway; William R Sellers; Steven P Gygi Journal: Cell Date: 2020-01-23 Impact factor: 41.582
Authors: Peter S Kim; Todd D Armstrong; Hong Song; Matthew E Wolpoe; Vivian Weiss; Elizabeth A Manning; Lan Qing Huang; Satoshi Murata; George Sgouros; Leisha A Emens; R Todd Reilly; Elizabeth M Jaffee Journal: J Clin Invest Date: 2008-05 Impact factor: 14.808